Hikma Pharmaceuticals Share Price (HIK)

1,208.00 +23.50 (+1.98%) delayed: 7:02PM BST
Bid price 1,208.00 Open price 1,187.50
Ask price 1,209.50 Prev close 1,208.00
High price 1,248.00 Spread 0.12%
Low price 1,183.35 Volume 649,028

Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.

Hikma Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hikma Pharmaceuticals share price charts

Hikma Pharmaceuticals Share Price Information

Name Hikma Pharmaceuticals Epic HIK
Sector Pharmaceuticals & Biotechnology ISIN GB00B0LCW083
Activites Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. Index FTSE 250

Hikma Pharmaceuticals Key Numbers

Latest Share Price (p) 1,208.00 Net Gearing (%) 48.20
Market Capitalisation (£m) 2,853.07 Gross Gearing (%) 54.90
Shares in issue (m) 240.87 Debt Ratio 41.03
P/E Ratio -3.37 Debt-to-Equity Ratio 0.57
Total dividends per share (p) 34.00 Assets / Equity Ratio 2.22
Dividend Yield (%) 1.84 Price to book value 1.87
Dividend cover (x) 0.00 ROCE (%) -28.48
Earning per share (p) -351.80 EPS Growth (%) -629.02
52 week high / low 2,000.00 / 814.20 DPS Growth (%) 3.03

Hikma Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
19/03/2018 TIN Mazen Darwazah ED 38,501
19/03/2018 TIN Said Darwazah CH 68,346
31/05/2017 TIN Mazen Darwazah ED 38,088
31/05/2017 TIN Said Darwazah CH 52,164
15/05/2017 TIN Mazen Darwazah ED 30,000

More Hikma Pharmaceuticals Director Deals >>

Hikma Pharmaceuticals Company News

09:28 20/04/2018

Hikma launches injection to reduce severity of cardiomyopathy

Hikma Pharmaceuticals said Friday its wholly-owned US subsidiary West-Ward Pharmaceuticals launched an injection to reduce the incidence and severity of cardiomyopathy, a chronic heart disease, in certain women with breast cancer. West-Ward launched Dexrazoxane for injection, the generic...

09:00 20/04/2018

Hikma launches Dexrazoxane for Injection

RNS Number : 5333L Hikma Pharmaceuticals Plc 20 April 2018   London, 20 April 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary West-Ward...

12:00 19/04/2018

Annual Financial Report and Notice of AGM

RNS Number : 4724L Hikma Pharmaceuticals Plc 19 April 2018     Hikma Pharmaceuticals PLC (the 'Company') Publication of 2017 Annual Report and Notice of AGM LEI: 549300BNS685UXH4JI75 The Company will today publish on its website, www.hikma.com , the Annual...

More Hikma Pharmaceuticals Company News >>

Register now for FREE Hikma Pharmaceuticals company news

Hikma Pharmaceuticals Share Price Discussions

more than 1 year ago

Hikma Pharmaceuticals (HIK)

Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...

Register now for FREE Hikma Pharmaceuticals share price discussions